Oligodendroglioma: Impact of molecular biology on its definition, diagnosis and management

Neuropathology

Volumn 25, Issue 3, 2005, Pages 247-253

  Ueki, Keisuke ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemosensitivity; Molecular diagnosis; Oligodendroglioma

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CONFERENCE PAPER; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROPATHOLOGY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR DIAGNOSIS; ANIMAL; BRAIN TUMOR; CLASSIFICATION; GENE EXPRESSION; GENETICS; PATHOLOGY; REVIEW;

ANIMALS; BRAIN NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR BIOLOGY; OLIGODENDROGLIOMA;

EID: 27244436435     PISSN: 09196544     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2005.00637.x     Document Type: Conference Paper

References (30)

1. Kleihues P, Louis DN, Scheithauer BW et al The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225; discussion 226-219.
2. Burger PC. What is an oligodendroglioma? Brain Pathol 2002; 12: 257-259.
3. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360-364.
4. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46: 203-207.
5. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000; 54: 1442-1448.
6. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986; 322: 644-647.
7. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993; 3: 19-26.
8. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-223; discussion 223-214.
9. Kraus JA, Koopmann J, Kaskel P et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91-95.
10. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-1479.
11. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Clin Oncol 2000; 18: 636-645.
12. Ueki K, Nishikawa R, Nakazato Y et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201.
13. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 1Oq loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001; 159: 359-367.
14. Burger PC, Minn AY, Smith JS et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001; 14: 842-853.
15. Sasaki H, Zlatescu MC, Betensky RA et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendro-glioma". J Neuropathol Exp Neurol 2002; 61: 58-63.
16. Temple S. The development of neural stem cells. Nature 2001; 414: 112-117.
17. Marie Y, Sanson M, Mokhtari K et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001; 358: 298-300.
18. Lu QR, Park JK, Noll E et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 2001; 98: 10851-10856.
19. Riemenschneider MJ, Koy TH, Reifenberger G. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol (Berl) 2004; 107: 277-282.
20. Bouvier C, Bartoli C, Aguirre-Cruz L et al Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg 2003; 99: 344-350.
21. Ligon KL, Alberta JA, Kho AT et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004; 63: 499-509.
22. Mukasa A, Ueki K, Matsumoto S et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002; 21: 3961-3968.
23. Mukasa A, Ueki K, Ge X et al. Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 2004; 14: 34-42.
24. Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 2002; 61: 947-955.
25. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001; 15: 1913-1925.
26. Singh SK, Hawkins C, Clarke ID et al Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
27. Yuan X, Curtin J, Xiong Y et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23: 9392-9400.
28. Zlatescu MC, TehraniYazdi A, Sasaki H et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001; 61: 6713-6715.
29. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005; 113: 379-385.
30. Dong SM, Pang JC, Poon WS et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001; 60: 808-816.